{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-092680","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-08-21T21:12:40+00:00","discovered_at":"2026-08-21T21:14:03.056322+00:00","generated_at":"2026-08-21T21:14:09.557713+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty","bullets":["On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).","Assigned rights include 100% of Apitox Korean medicine-clinic market rights and 25% royalty on US Apitox economic proceeds.","Also granted 25% revenue participation on net proceeds from overseas rights deals plus quarterly clinical and commercialization updates.","Company assumes no pre-effective-date liabilities; rights exclude global rights not held by FreeT and underlying Apitox IP.","FreeT will support continued development and expansion and pursue future grants of non-US Apitox territories to Apimeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-092680","json":"https://secwatch.observer/filing/0001213900-26-092680.json","markdown":"https://secwatch.observer/filing/0001213900-26-092680.md","text":"https://secwatch.observer/filing/0001213900-26-092680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/0001213900-26-092680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/ea0303076-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-21T21:14:09.557713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}